SAN FRANCISCO, CALIFORNIA — September 4, 2025 — Leads & Copy — GT Biopharma, Inc. (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and Chief Executive Office, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City, September 8-10, 2025. The company is available for one-on-one meetings at the conference. A webcast of the company’s presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025.
The Phase 1 trial evaluating GTBP-3650 for relapsed or refractory CD33 expressing hematologic malignancies continues to enroll as expected, and the company expects to release initial results from multiple dose cohorts later in 2025. GT Biopharma is also on track for GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors in Q4 2025.
Corey Davis, Ph.D., LifeSci Advisors, cdavis@lifesciadvisors.com, 212-915-2577
Source: GT Biopharma, Inc.
